je.st
news
Tag: disease
Climate change behind mysterious kidney disease: Study
2015-10-09 03:53:00| Climate Ark Climate Change & Global Warming Newsfeed
Economic Times: A mysterious kidney disease that has killed over 20,000 people in Central America since 2002, and now spreading to other countries including India, may be caused by chronic, severe dehydration linked to global climate change, says a new study. "This could be the first epidemic directly caused by global warming," said one of the researchers Richard Johnson, professor of medicine at the University of Colorado School of Medicine in the US. So far, the manual labourers on sugar cane plantations...
Tags: change
study
disease
climate
Legionnaires Disease Bacteria Found In Hospital Sinks
2015-10-07 04:24:45| Food - Topix.net
Bacteria that causes Legionnaires Disease has been found in two sinks at the VA Hospital in Pittsburgh. It was discovered in separate staff areas of the H.J. Heinz campus in O'Hara.
Tags: found
hospital
disease
bacteria
Results from Mercks Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet
2015-10-06 01:01:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the publication of results from C-SURFER, the first Phase 31 clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-nave and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection. Language: English Contact: MerckMedia Contacts:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
FDA Approves KEYTRUDA (pembrolizumab) for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Containing Chemotherapy
2015-10-02 20:49:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Patients with EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression on FDA-Approved Therapy for These Aberrations Prior to Receiving KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA (pembrolizumab) monotherapy, the companys anti-PD-1 (programmed death receptor-1) therapy, at a dose of 2 mg/kg every three weeks, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test and who have disease progression on or after platinum-containing chemotherapy. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: or
express
cell
treatment
Update on Swine Enteric Coronavirus Disease in US
2015-10-01 02:00:00| ThePigSite - Industry News
US - The number of pig farm samples that were confirmed positive for porcine epidemic diarrhoea virus (PEDV) in the last week was 15. There have been no premises confirmed with having porcine delta coronavirus (PDCoV) or the dual infection (PEDV and PDCoV), in the 24 September 2015 weekly report.
Sites : [66] [67] [68] [69] [70] [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] next »